Influence of the Host Microbiome on the Mechanism of FVIII Immunogenicity: Project 3
宿主微生物组对 FVIII 免疫原性机制的影响:项目 3
基本信息
- 批准号:10406335
- 负责人:
- 金额:$ 18.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-05-01 至 2024-04-30
- 项目状态:已结题
- 来源:
- 关键词:AcetatesAddressAgeAnimalsAntibiotic TherapyAntibioticsAntibodiesAntigen-Presenting CellsAreaBiologicalBlood Coagulation DisordersButyratesBypassCell CommunicationComplexComplicationDevelopmentDietDiseaseEnvironmentEnvironmental Risk FactorEvaluationEvolutionExposure toF8 geneFactor VIIIGenerationsGeneticGenetic EngineeringGenotypeGerm-FreeGut associated lymphoid tissueHemophilia AHemostatic AgentsHumanImageImmuneImmune ToleranceImmune responseImmune systemIncidenceInfusion proceduresInheritedInterventionIntravenousInvestigationIsoantibodiesKnowledgeLabelLifeLiverLocationMediatingModificationMolecularMucous MembraneMusMutationNatural ImmunityNutrientOralOutcomePathogenesisPatient CarePatientsPersonsPharmaceutical PreparationsPlasmaPlayPopulationPredisposing FactorPropionatesProtocols documentationRecurrenceRegimenRegulationReplacement TherapyResearchRiskRoleSecondary toSeriesSpleenSurfaceT-LymphocyteT-Lymphocyte SubsetsTestingTimeTryptophan Metabolism PathwayVolatile Fatty Acidsadaptive immune responseadaptive immunityantibody inhibitorboysclinical carecofactorcostcytokinedietarydysbiosisexperimental studyfecal transplantationgut microbesgut microbiomegut microbiotahost microbiomeimmunogenicityimmunopathologyinfancyinhibitorintravenous administrationmalemicrobialmicrobiomemicrobiotamouse modelmutantprogramsprophylacticsecondary lymphoid organsuccesstraffickingtranslational potential
项目摘要
Project
3
Abstract
The development of an immune response to factor VIII (FVIII) in ~30% of persons with severe hemophilia
A (HA) represents the most important complication of treating this condition. The formation of anti-FVIII
antibodies (inhibitors) significantly compromises the clinical care of these patients, and their subsequent
management is less predictable, practically challenging and often extraordinarily costly. The
pathogenesis of FVIII inhibitors is recognized to be complex and multifactorial. Most patients that develop
this complication do so during the first 25 exposures to FVIII replacement therapy, within the first 2-3
years of life. While there are clear genetic predisposing factors for inhibitor development, such as the
mutant F8 genotype, a range of acquired influences also contribute to inhibitor risk. In this project, we will
investigate the role of an environmental factor that, to date, has not been studied in this context – the gut
microbiome. There is substantive evidence that the gut microbiome plays an important role in the
development and regulation of the systemic immune system, and that there are clear associations
between the gut microbiota and certain forms of immunopathology. In addition, the microbiome
undergoes significant changes during the first two years of life, the time when initial FVIII treatment occurs
in boys with severe HA, and the period of maximum risk for FVIII inhibitor generation. In Project 3 of this
research program we will address three objectives related to microbiome influences on FVIII inhibitor
formation. We will first evaluate the influence of changes to the gut microbiome-related metabolite
environment on the immunogenicity of FVIII. In particular, we will determine whether the products of
tryptophan metabolism and levels of the short chain fatty acids, acetate, butyrate and propionate
influence innate and adaptive immune responses to intravenously administered FVIII. In the second
series of experiments, we will conduct studies utilizing our recently developed germ-free HA mouse
model. In these studies, we will begin with an assessment of the likelihood for FVIII inhibitor development
in the absence of gut microbes, and will then progress to studies in which we selectively repopulate the
gut microbiota through various strategies including fecal transplantation from HA mice with and without
FVIII inhibitors. Lastly, we will conduct studies to evaluate the role of the gut microbiome in regulating the
immune response to orally delivered FVIII. These experiments will assess the interaction of FVIII with
various antigen presenting cell populations and will determine the cytokine and T cell context of the FVIII
immune response in the gut associated lymphoid tissue, liver and spleen. Overall, we propose that this
program of research will provide important new knowledge concerning the role of the gut microbiome and
FVIII immunogenicity. This new information is very likely to have significant biological and potential
translational implications.
项目
3
摘要
在约30%的重度血友病患者中发生对凝血因子VIII(FVIII)的免疫应答
A(HA)是治疗这种疾病最重要的并发症。抗FVIII抗体的形成
抗体(抑制剂)显著损害了这些患者的临床护理,
管理的可预测性较低,在实践中具有挑战性,而且往往费用高昂。的
FVIII抑制剂的发病机制被认为是复杂和多因素的。大多数患者
这种并发症在前25次暴露于FVIII替代治疗期间发生,在前2-3次暴露期间发生,
多年的生活。虽然有明显的遗传易感因素抑制剂的发展,如
突变的F8基因型,一系列获得性影响也有助于抑制剂的风险。在这个项目中,我们将
调查一个环境因素的作用,迄今为止,还没有在这种情况下研究-肠道
微生物组有实质性证据表明,肠道微生物组在消化道疾病中起着重要作用。
发展和调节系统免疫系统,并有明确的关联
肠道菌群和某些形式的免疫病理学之间的联系。此外,微生物群
在出生后的头两年(即首次FVIII治疗时)发生显著变化
在重度HA男孩中,以及FVIII抑制物生成的最大风险期。在项目3中,
研究计划,我们将解决与微生物群对FVIII抑制剂影响相关的三个目标
阵我们将首先评估肠道微生物组相关代谢物变化的影响
环境对FVIII免疫原性的影响。特别是,我们将确定产品是否
色氨酸代谢和短链脂肪酸、乙酸、丁酸和丙酸的水平
影响对静脉内施用的FVIII的先天性和适应性免疫应答。在第二
在一系列实验中,我们将利用我们最近开发的无菌HA小鼠进行研究
模型在这些研究中,我们将开始评估FVIII抑制物形成的可能性
在没有肠道微生物的情况下,然后将进行研究,我们选择性地重新填充
肠道微生物群通过各种策略,包括粪便移植从HA小鼠与和没有
FVIII抑制剂。最后,我们将进行研究,以评估肠道微生物组在调节
口服FVIII的免疫应答。这些实验将评估FVIII与
各种抗原呈递细胞群,并将决定FVIII的细胞因子和T细胞背景
肠道相关淋巴组织、肝脏和脾脏中的免疫应答。总的来说,我们建议,
研究计划将提供有关肠道微生物组作用的重要新知识,
FVIII免疫原性。这一新的信息很可能具有重大的生物学意义和潜力
翻译的含义。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID P LILLICRAP其他文献
DAVID P LILLICRAP的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID P LILLICRAP', 18)}}的其他基金
Project 3: Contribution of Non-VWF Genomic Variants to Quantitative Von Willebrand Factor Pathologies
项目 3:非 VWF 基因组变异对定量冯维勒布兰德因子病理学的贡献
- 批准号:
10113378 - 财政年份:2019
- 资助金额:
$ 18.6万 - 项目类别:
Project 3: Contribution of Non-VWF Genomic Variants to Quantitative Von Willebrand Factor Pathologies
项目 3:非 VWF 基因组变异对定量冯维勒布兰德因子病理学的贡献
- 批准号:
10379437 - 财政年份:2019
- 资助金额:
$ 18.6万 - 项目类别:
Project 3: Contribution of Non-VWF Genomic Variants to Quantitative Von Willebrand Factor Pathologies
项目 3:非 VWF 基因组变异对定量冯维勒布兰德因子病理学的贡献
- 批准号:
10584537 - 财政年份:2019
- 资助金额:
$ 18.6万 - 项目类别:
Influence of the Host Microbiome on the Mechanism of FVIII Immunogenicity: Project 3
宿主微生物组对 FVIII 免疫原性机制的影响:项目 3
- 批准号:
10162327 - 财政年份:2018
- 资助金额:
$ 18.6万 - 项目类别:
Core A-ADMINISTRATIVE AND CLINICAL ACQUISITION CORE
核心 A-管理和临床获取核心
- 批准号:
7114036 - 财政年份:2005
- 资助金额:
$ 18.6万 - 项目类别:
Core A-ADMINISTRATIVE AND CLINICAL ACQUISITION CORE
核心 A-管理和临床获取核心
- 批准号:
7524665 - 财政年份:
- 资助金额:
$ 18.6万 - 项目类别:
Core A-ADMINISTRATIVE AND CLINICAL ACQUISITION CORE
核心 A-管理和临床获取核心
- 批准号:
7524670 - 财政年份:
- 资助金额:
$ 18.6万 - 项目类别:
Core A-ADMINISTRATIVE AND CLINICAL ACQUISITION CORE
核心 A-管理和临床获取核心
- 批准号:
7652348 - 财政年份:
- 资助金额:
$ 18.6万 - 项目类别:
Project 3: Contribution of Non-VWF Genomic Variants to Quantitative Von Willebrand Factor Pathologies
项目 3:非 VWF 基因组变异对定量冯维勒布兰德因子病理学的贡献
- 批准号:
9891092 - 财政年份:
- 资助金额:
$ 18.6万 - 项目类别:
Core A-ADMINISTRATIVE AND CLINICAL ACQUISITION CORE
核心 A-管理和临床获取核心
- 批准号:
7885358 - 财政年份:
- 资助金额:
$ 18.6万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 18.6万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 18.6万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 18.6万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 18.6万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 18.6万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 18.6万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 18.6万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 18.6万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 18.6万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 18.6万 - 项目类别:
Research Grant